Antiaggregant Activity of a New Benzimidazole Derivative

Antiaggregant Activity of a New Benzimidazole Derivative

Antiaggregant activity of a new tricyclic benzimidazole derivative, RU-891 compound, was studied on the model of ADP-induced platelet aggregation in vitro and intravascular platelet aggregation in vivo . We evaluated the effect of this substance on blood coagulation potential. Antiaggregant agent ac...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bulletin of experimental biology and medicine 2014-04, Vol.156 (6), p.796-798
Hauptverfasser: Kucheryavenko, A. F., Spasov, A. A., Petrov, V. I., Anisimova, V. A.
Format: Artikel
Sprache:eng
Schlagworte:
Animals
Aspirin
Benzimidazoles - pharmacology
Benzimidazoles - toxicity
Biomedical and Life Sciences
Biomedicine
Blood Coagulation - drug effects
Cell Biology
Dose-Response Relationship, Drug
Internal Medicine
Laboratory Medicine
Lethal Dose 50
Pathology
Platelet Aggregation - drug effects
Rabbits
Rats
Ruthenium
Salicylates
Statistics, Nonparametric
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Antiaggregant activity of a new tricyclic benzimidazole derivative, RU-891 compound, was studied on the model of ADP-induced platelet aggregation in vitro and intravascular platelet aggregation in vivo . We evaluated the effect of this substance on blood coagulation potential. Antiaggregant agent acetylsalicylic acid was used as the reference drug. RU-891 produced a dose-dependent antiaggregant effect in vivo and in vitro that exceeded the effect of the reference drug. This compound did not modulate blood coagulation potential.
ISSN:0007-4888
1573-8221
DOI:10.1007/s10517-014-2453-9